Adaptive Biotechnologies (ADPT) Consolidated Net Income (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Consolidated Net Income data on file, last reported at -$20.0 million in Q1 2026.

• Quarterly Consolidated Net Income rose 32.9% year-over-year to -$20.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$49.6 million (up 65.01% YoY) and the FY2025 annual result came in at -$59.5 million, up 62.75% from the prior year.
• Consolidated Net Income fell to -$20.0 million in Q1 2026 per ADPT's latest filing, from -$13.6 million in the prior quarter.
• The five-year high for Consolidated Net Income was $9.5 million in Q3 2025, with the low at -$69.5 million in Q4 2023.
• Average Consolidated Net Income over 5 years is -$39.1 million, with a median of -$45.3 million recorded in 2022.
• Year-over-year, Consolidated Net Income slumped 72.94% in 2023 and surged 129.74% in 2025.
• Adaptive Biotechnologies' Consolidated Net Income stood at -$40.2 million in 2022, then tumbled by 72.94% to -$69.5 million in 2023, then soared by 51.46% to -$33.7 million in 2024, then surged by 59.73% to -$13.6 million in 2025, then sank by 47.4% to -$20.0 million in 2026.
• Business Quant data shows ADPT's Consolidated Net Income at -$20.0 million in Q1 2026, -$13.6 million in Q4 2025, and $9.5 million in Q3 2025.